Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer

Linlin Ma, Yuqian Yan, Yang Bai, Yinhui Yang, Yunqian Pan, Xiaokun Gang, Robert Jeffrey Karnes, Jun Zhang, Qiubo Lv, Qiang Wu, Haojie Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target. Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive. Methods: Analysis of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed. ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to determine the mechanism by which EZH2 represses FOXO1 expression. Immunohistochemistry was employed to assess the correlation between EZH2 and FOXO1 protein expression in prostate cancer patient specimens. In vitro MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and animal experiments were performed to determine the anti-cancer efficacy of EZH2 inhibitor alone or in combination of docetaxel, a chemotherapy agent of the taxane family, and dependency of the efficacy on FOXO1 expression. Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter. EZH2 represses FOXO1 gene expression at the transcriptional level. EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens. This repression requires the methyltransferase activity and the functional PRC2 complex. While effectively inducing loss of viability of PTEN-positive 22Rv1 prostate cancer cells, EZH2 inhibitor failed to inhibit growth of PTEN-negative C4-2 prostate cancer cells. Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-negative cancer cells in vitro and in mice. This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1. Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death. Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.

Original languageEnglish (US)
Pages (from-to)5020-5034
Number of pages15
JournalTheranostics
Volume9
Issue number17
DOIs
StatePublished - Jan 1 2019

Fingerprint

docetaxel
Prostatic Neoplasms
Neoplasms
Polycomb-Group Proteins
Forkhead Transcription Factors
taxane
Sequence Deletion
Methyltransferases
Cell Death
Therapeutics
Down-Regulation
Western Blotting
Immunohistochemistry
Gene Expression
Drug Therapy
Growth
Genes
Proteins

Keywords

  • Cancer
  • Cell death
  • EZH2
  • FOXO1
  • PTEN
  • Taxane

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer. / Ma, Linlin; Yan, Yuqian; Bai, Yang; Yang, Yinhui; Pan, Yunqian; Gang, Xiaokun; Karnes, Robert Jeffrey; Zhang, Jun; Lv, Qiubo; Wu, Qiang; Huang, Haojie.

In: Theranostics, Vol. 9, No. 17, 01.01.2019, p. 5020-5034.

Research output: Contribution to journalArticle

Ma, L, Yan, Y, Bai, Y, Yang, Y, Pan, Y, Gang, X, Karnes, RJ, Zhang, J, Lv, Q, Wu, Q & Huang, H 2019, 'Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer', Theranostics, vol. 9, no. 17, pp. 5020-5034. https://doi.org/10.7150/thno.34700
Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X et al. Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer. Theranostics. 2019 Jan 1;9(17):5020-5034. https://doi.org/10.7150/thno.34700
Ma, Linlin ; Yan, Yuqian ; Bai, Yang ; Yang, Yinhui ; Pan, Yunqian ; Gang, Xiaokun ; Karnes, Robert Jeffrey ; Zhang, Jun ; Lv, Qiubo ; Wu, Qiang ; Huang, Haojie. / Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer. In: Theranostics. 2019 ; Vol. 9, No. 17. pp. 5020-5034.
@article{22456818f820457fa097040cd2a5b6b2,
title = "Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer",
abstract = "Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target. Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive. Methods: Analysis of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed. ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to determine the mechanism by which EZH2 represses FOXO1 expression. Immunohistochemistry was employed to assess the correlation between EZH2 and FOXO1 protein expression in prostate cancer patient specimens. In vitro MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and animal experiments were performed to determine the anti-cancer efficacy of EZH2 inhibitor alone or in combination of docetaxel, a chemotherapy agent of the taxane family, and dependency of the efficacy on FOXO1 expression. Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter. EZH2 represses FOXO1 gene expression at the transcriptional level. EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens. This repression requires the methyltransferase activity and the functional PRC2 complex. While effectively inducing loss of viability of PTEN-positive 22Rv1 prostate cancer cells, EZH2 inhibitor failed to inhibit growth of PTEN-negative C4-2 prostate cancer cells. Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-negative cancer cells in vitro and in mice. This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1. Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death. Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.",
keywords = "Cancer, Cell death, EZH2, FOXO1, PTEN, Taxane",
author = "Linlin Ma and Yuqian Yan and Yang Bai and Yinhui Yang and Yunqian Pan and Xiaokun Gang and Karnes, {Robert Jeffrey} and Jun Zhang and Qiubo Lv and Qiang Wu and Haojie Huang",
year = "2019",
month = "1",
day = "1",
doi = "10.7150/thno.34700",
language = "English (US)",
volume = "9",
pages = "5020--5034",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "17",

}

TY - JOUR

T1 - Overcoming EZH2 inhibitor resistance by taxane in PTEN-mutated cancer

AU - Ma, Linlin

AU - Yan, Yuqian

AU - Bai, Yang

AU - Yang, Yinhui

AU - Pan, Yunqian

AU - Gang, Xiaokun

AU - Karnes, Robert Jeffrey

AU - Zhang, Jun

AU - Lv, Qiubo

AU - Wu, Qiang

AU - Huang, Haojie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target. Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive. Methods: Analysis of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed. ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to determine the mechanism by which EZH2 represses FOXO1 expression. Immunohistochemistry was employed to assess the correlation between EZH2 and FOXO1 protein expression in prostate cancer patient specimens. In vitro MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and animal experiments were performed to determine the anti-cancer efficacy of EZH2 inhibitor alone or in combination of docetaxel, a chemotherapy agent of the taxane family, and dependency of the efficacy on FOXO1 expression. Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter. EZH2 represses FOXO1 gene expression at the transcriptional level. EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens. This repression requires the methyltransferase activity and the functional PRC2 complex. While effectively inducing loss of viability of PTEN-positive 22Rv1 prostate cancer cells, EZH2 inhibitor failed to inhibit growth of PTEN-negative C4-2 prostate cancer cells. Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-negative cancer cells in vitro and in mice. This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1. Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death. Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.

AB - Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target. Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulated in human cancers such as prostate cancer although the underlying regulatory mechanisms remain elusive. Methods: Analysis of EZH2 ChIP-seq and ChIP-on-chip data in various cell types was performed. ChIP-qPCR, RT-qPCR, and western blot analyses were conducted to determine the mechanism by which EZH2 represses FOXO1 expression. Immunohistochemistry was employed to assess the correlation between EZH2 and FOXO1 protein expression in prostate cancer patient specimens. In vitro MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and animal experiments were performed to determine the anti-cancer efficacy of EZH2 inhibitor alone or in combination of docetaxel, a chemotherapy agent of the taxane family, and dependency of the efficacy on FOXO1 expression. Results: We demonstrated that EZH2 binds to the FOXO1 gene promoter. EZH2 represses FOXO1 gene expression at the transcriptional level. EZH2 protein level inversely correlated with FOXO1 protein expression in prostate cancer patient specimens. This repression requires the methyltransferase activity and the functional PRC2 complex. While effectively inducing loss of viability of PTEN-positive 22Rv1 prostate cancer cells, EZH2 inhibitor failed to inhibit growth of PTEN-negative C4-2 prostate cancer cells. Co-treatment with docetaxel overcame EZH2 inhibitor resistance in PTEN-negative cancer cells in vitro and in mice. This effect was largely mediated by docetaxel-induced nuclear localization and activation of FOXO1. Conclusions: This study identifies FOXO1 as a bona fide repression target of EZH2 and an essential mediator of EZH2 inhibition-induced cell death. Our findings suggest that EZH2 repression of FOXO1 can be targeted by EZH2 inhibitor as a monotherapy for PTEN-proficient cancers or in combination with taxane for treatment of cancers with PTEN mutation or deletion.

KW - Cancer

KW - Cell death

KW - EZH2

KW - FOXO1

KW - PTEN

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=85070483670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070483670&partnerID=8YFLogxK

U2 - 10.7150/thno.34700

DO - 10.7150/thno.34700

M3 - Article

C2 - 31410199

AN - SCOPUS:85070483670

VL - 9

SP - 5020

EP - 5034

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 17

ER -